Abstract: Poster Presentations |

An Overview of the Efficacy of Gemifloxacin for the Treatment of Community-Acquired Pneumonia (CAP) FREE TO VIEW

Glenn S. Tillotson, MS; Lionel Mandell, MD; Brian Carlin, MD*
Author and Funding Information

Alleghany General Hospital, Pittsburgh, PA


Chest. 2004;126(4_MeetingAbstracts):847S-c-848S. doi:10.1378/chest.126.4_MeetingAbstracts.847S-c
Text Size: A A A
Published online


PURPOSE:  To assess the efficacy of once daily gemifloxacin in the treatment of CAP.

METHODS:  Six clinical studies were conducted with adult patients suffering from CAP. Gemifloxacin (320mg qd 7 or14 days) was compared to amoxicillin/clavulanate (1g/125mg tid 10 days), cefuroxime/clarithromycin (500mg/500mg bid 7 or14 days), trovafloxacin (200mg qd 7 or14 days) and IV ceftriaxone/oral cefuroxime (2g qd/500mg bid 1–7 days + 1–13 days). Outcome measures were clinical, bacteriological, and radiological responses at follow-up.

RESULTS:  Clinical resolution was 90.5% for the combined gemifloxacin group compared with 91.1% for the combined comparators. Bacteriological response rates were 88.9% for gemifloxacin and 88.7% for the combined comparator group. Radiological response rates were between 87.9% and 94.0% for gemifloxacin and between 87.6% and 94.2% for the comparators. Gemifloxacin achieved 100% (12/12) eradication of penicillin-resistant S. pneumoniae (MIC ≥2ug/mL ) and was similarly effective in patients with macrolide-resistant S. pneumoniae. 14/16 (87.5%) patients with erythromycin-resistant S. pneumoniae and 19/22 (86.4%) patients with clarithromycin-resistant S. pneumoniae achieved clinical and bacteriological success at follow-up. Gemifloxacin was effective against CAP due to multi-drug resistant S. pneumoniae (MDRSP), i.e., S. pneumoniae resistant to 2 or more of the following: penicillin, second generation cephalosporins, macrolides, tetracyclines and TMP/SMX. Of 22 patients with MDRSP treated for 7 days, 19 (86.5%) achieved clinical and bacteriological success at follow-up. Of the pathogens isolated from these patients, 11 were penicillin-resistant, 19 macrolide-resistant, 16 TMP-SMX-resistant, 16 tetracycline-resistant and 14 resistant to a second generation cephalosporin.

CONCLUSION:  Gemifloxacin 320 mg once daily for 7 days was found to be at least as effective clinically, bacteriologically and radiologically as the comparator regimens for the treatment of CAP.

CLINICAL IMPLICATIONS:  Gemifloxacin offers an effective new option in the treatment of CAP.

DISCLOSURE:  B. Carlin, None.

Wednesday, October 27, 2004

12:30 PM- 2:00 PM




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543